GSK qui­et­ly re­veals just how much cash they used to buy a chunk of the Bay Area's buzzi­est start­up

As we re­port­ed last fall, Glax­o­SmithK­line R&D chief Hal Bar­ron was gung ho over the prospects of team­ing up with Rick Klaus­ner and his start­up Lyell Im­munophar­ma. Their al­liance was billed as a path to cell ther­a­py 2.0 — in­clud­ing key play­ers in over­com­ing the lim­i­ta­tions to Gen­er­a­tion 1. But the phar­ma gi­ant wasn’t keen to pub­licly dis­close just how much mon­ey was go­ing in­to Lyell.

Un­til now, when the ac­coun­tants and lawyers are in charge of pub­lic dis­clo­sures.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER